Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drugs in Development, 2021

October 2021 | 122 pages | ID: SAE10522F3D1EN
Global Markets Direct

Abstracts

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drugs in Development, 2021

SUMMARY

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 6, 5 and 15 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Infectious Disease, Genito Urinary System And Sex Hormones, Oncology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Dermatology and Musculoskeletal Disorders which include indications Glaucoma, Pulmonary Arterial Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronavirus Disease 2019 (COVID-19), Diabetic Nephropathy, Diabetic Retinopathy, Neuroinflammation, Ocular Hypertension, Pulmonary Hypertension, Sickle Cell Disease With Vaso-Occlusive Crisis, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cognitive Impairment Associated With Schizophrenia (CIAS), Colorectal Cancer, Critical Limb Ischemia, Diabetic Foot Ulcers, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Hypertension, Idiopathic Pulmonary Hypertension, Ischemic Stroke, Kidney Disease (Nephropathy), Liver Diseases, Liver Fibrosis, Lung Disease, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pneumonia, Pressure Ulcers, Prostate Cancer, Raynauds Disease, Schizophrenia, Skin Ulcers, Stable Angina, Stroke, Systolic Heart Failure, Tinea Pedis (Athlete Foot), Unspecified Cardiovascular Disorders and Vascular Dementias.

The latest report Soluble Guanylate Cyclase - Drugs In Development, 2021, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
• The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Akebia Therapeutics Inc, 2021
Pipeline by AntiRadical Therapeutics LLC, 2021
Pipeline by Bayer AG, 2021
Pipeline by Boehringer Ingelheim International GmbH, 2021
Pipeline by Cyclerion Therapeutics Inc, 2021
Pipeline by Gurus BioPharm, 2021
Pipeline by Innovative Pharmacological Research (IPHAR) Co Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by NicOx SA, 2021
Pipeline by Nitric Oxide Innovations LLC, 2021
Pipeline by Novan Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by Novoteris LLC, 2021
Pipeline by Toa Eiyo Ltd, 2021
Pipeline by Topadur Pharma AG, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Dormant Products, 2021 (Contd..4)
Dormant Products, 2021 (Contd..5)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021